SecurityTSBK / Timberland Bancorp, Inc. (887098101)
President and CEOSAND MICHAEL R
IndustrySavings Institutions, Not Federally Chartered
Institutional Owners75
Institutional Shares4,665,397 - 63.08%
Common Stock Shares Outstanding7,395,927 shares (as of 2018-06-30)
Institutional Value$ 231,480,000 USD
Related TBSK / TIMBERLAND BANCORP INC

Institutional Stock Ownership and Shareholders

TSBK / Timberland Bancorp, Inc. Institutional Ownership

Timberland Bancorp, Inc. (NASDAQ:TSBK) has 75 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 4,665,397 shares. Largest shareholders include Royce & Associates LLC, Dimensional Fund Advisors Lp, BlackRock Inc., Siena Capital Partners I, L.P., Renaissance Technologies LLC, Siena Capital Management, LLC, Vanguard Group Inc, Cutler Capital Management, LLC, BlackRock Institutional Trust Company, N.A., and State Street Corp.
Timberland Bancorp, Inc. (NASDAQ:TSBK) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 5,859 5,691 -2.87 178 213 19.66
2018-08-14 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC 300 0 -100.00 9 0 -100.00
2018-08-10 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 1,600 1,600 0.00 48 60 25.00
2018-08-14 13F-HR Pinnacle Holdings, LLC 1,000 1,000 0.00 30,400 37,340 22.83
2017-10-26 13F-HR Acrospire Investment Management LLC 2,039 0 -100.00 52 0 -100.00
2018-08-14 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 105,318 105,718 0.38 3,202 3,948 23.30
2018-08-06 13F-HR Bowling Portfolio Management LLC 25,976 22,242 -14.37 790 831 5.19
2018-08-08 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 20,876 20,900 0.11 635 781 22.99
2018-08-14 13F-HR ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 12,915 9,115 -29.42 393 340 -13.49
2018-08-08 13F-HR AMERICAN INTERNATIONAL GROUP INC 3,978 4,251 6.86 121 159 31.40
2018-08-10 13F-HR Opus Capital Group, LLC 21,790 814
2018-08-06 13F-HR Mcilrath & Eck, Llc 650 650 0.00 20 24 20.00
2018-08-14 13F-HR WESTPORT ASSET MANAGEMENT INC 93,093 93,093 0.00 2,830 2,830 0.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 155,877 124,850 -19.90 2,455 2,579 5.05
2018-08-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 1,050 1,050 0.00 32 32 0.00
2018-08-06 13F-HR STRS OHIO 16,700 18,300 9.58 507 683 34.71
2018-08-10 13F-HR GREAT WEST LIFE ASSURANCE CO /CAN/ 38 38 0.00 1 1 0.00
2018-08-22 13F-HR PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO 18,237 26,192 43.62 554 978 76.53
2017-02-10 13F-HR BlackRock Fund Advisors 1,273 1,813 42.42 20 37 85.00
2018-08-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 15,676 13,994 -10.73 477 523 9.64
2018-08-09 13F-HR Royce & Associates LLC 594,189 690,258 16.17 18,063 25,774 42.69
2018-08-10 13F-HR CITIGROUP INC 2,509 1,949 -22.32 76 73 -3.95
2018-08-08 13F-HR Russell Investments Group, Ltd. 4,824 2,764 -42.70 147 103 -29.93
2018-07-23 13F-HR Kiley Juergens Wealth Management, Llc 0 2,100 0 78
2018-07-30 13F-HR/A BADGLEY PHELPS & BELL INC 5,526 206
2018-08-03 13F-HR Cutler Capital Management, LLC 273,771 216,478 -20.93 8,322 8,083 -2.87
2018-07-20 13F-HR Creative Planning 25,814 25,814 0.00 785 964 22.80
2018-08-10 13F-HR FEDERATED INVESTORS INC /PA/ 1,021 1,021 0.00 31 38 22.58
2018-08-08 13F-HR LSV ASSET MANAGEMENT 76,954 77,301 0.45 2,339 2,886 23.39
2018-08-14 13F-HR Tower Research Capital LLC (TRC) 0 53 0 2
2018-08-13 13F-HR Advisor Group, Inc. 4,179 1,479 -64.61 127 55 -56.69
2018-08-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 6,600 6,600 0.00 201 246 22.39
2018-07-27 13F-HR PIEDMONT INVESTMENT ADVISORS LLC 113 4
2018-08-13 13F-HR Hilton Capital Management, LLC 978 37
2018-08-14 13F-HR TWO SIGMA INVESTMENTS LLC 10,427 9,193 -11.83 317 343 8.20
2018-09-18 13F-HR/A NORTHERN TRUST CORP 75,916 76,155 0.31 2,308 2,844 23.22
2018-07-25 13F-HR BESSEMER GROUP INC 11,800 11,800 0.00 359 441 22.84
2018-08-14 13F-HR BARCLAYS PLC 1,660 841 -49.34 50 31 -38.00
2018-07-23 13F-HR DELTA ASSET MANAGEMENT LLC/TN 8,800 8,800 0.00 268 329 22.76
2018-08-14 13F-HR Invesco Ltd. 0 7,778 0 291
2018-08-13 13F-HR Renaissance Technologies LLC 347,500 10,564
2018-05-11 13F-HR Delpha Capital Management, Llc 154 0 -100.00 4 0 -100.00
2018-08-14 13F-HR MORGAN STANLEY 18,276 20,951 14.64 556 782 40.65
2018-07-19 13F-HR Siena Capital Management, LLC 348,586 305,418 -12.38 10,597 11,404 7.62
2018-08-13 13F-HR Ativo Capital Management LLC 37,011 35,011 -5.40 1,125 1,307 16.18
2018-07-25 13F-HR BNP PARIBAS ARBITRAGE, SA 1,365 220 -83.88 41,496 8,215 -80.20
2018-08-14 13F-HR ROYAL BANK OF CANADA 250 250 0.00 8 9 12.50
2018-08-15 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 40,000 40,000 0.00 1,216 1,494 22.86
2018-08-14 13F-HR PANAGORA ASSET MANAGEMENT INC 60,714 65,880 8.51 1,846 2,460 33.26
2018-08-13 13F-HR OXFORD ASSET MANAGEMENT 7,352 273
2018-08-10 13F-HR O'SHAUGHNESSY ASSET MANAGEMENT, LLC 7,266 7,298 0.44 221 273 23.53
2017-02-03 SC 13G Siena Capital Partners I, L.P. 375,899
2018-08-14 13F-HR VANGUARD GROUP INC 258,003 263,249 2.03 7,843 9,829 25.32
2018-08-14 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 9,478 9,985 5.35 288 373 29.51
2018-07-24 13F-HR MEEDER ASSET MANAGEMENT INC 470 837 78.09 14 31,253 223,135.71
2018-08-10 13F-HR Legal & General Group Plc 1,227 901 -26.57 37 34 -8.11
2018-08-14 13F-HR DEUTSCHE BANK AG\ 30,020 40,566 35.13 911 1,513 66.08
2018-08-06 13F-HR RHUMBLINE ADVISERS 6,214 232
2018-08-14 13F-HR TEACHERS ADVISORS INC 11,230 11,230 0.00 341 419 22.87
2018-07-19 13F-HR JAMES INVESTMENT RESEARCH INC 3,535 3,535 0.00 108 132 22.22
2018-07-24 13F-HR ACADIAN ASSET MANAGEMENT LLC 70,700 59,254 -16.19 2,151 2,214 2.93
2018-08-14 13F-HR JP Morgan Chase & Co 8,461 5,051 -40.30 257 189 -26.46
2018-08-02 13F-HR FIRST TRUST ADVISORS LP 14,510 17,403 19.94 441 650 47.39
2018-07-27 13F-HR FIRST QUADRANT L P/CA 1,924 1,924 0.00 58 72 24.14
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 50,501 55,353 9.61 1,535 2,066 34.59
2018-08-10 13F-HR DIMENSIONAL FUND ADVISORS LP 606,575 611,001 0.73 18,440 22,815 23.73
2018-08-14 13F-HR UBS Group AG 0 1,803 0 67
2018-08-09 13F-HR MARTINGALE ASSET MANAGEMENT L P 29,603 29,708 0.35 900 1,110 23.33
2018-05-11 13F-HR MARTINGALE ASSET MANAGEMENT L P 29,603 29,603 0.00 786 900 14.50
2018-08-14 13F-HR Context BH Capital Management, LP 80,116 80,116 0.00 2,436 2,992 22.82
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 4,687 175
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 72,261 72,090 -0.24 2,197 2,692 22.53
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 6,422 7,567 17.83 195 282 44.62
2018-08-14 13F-HR Parallax Volatility Advisers, L.P. 1 0 -100.00 0 0
2018-08-13 13F-HR Axa 16,400 8,300 -49.39 499 310 -37.88
2018-08-13 13F-HR Ameritas Investment Partners, Inc. 546 546 0.00 17 20 17.65
2018-05-11 13F-HR CITIGROUP INC 3,784 2,509 -33.69 100 76 -24.00
2018-08-14 13F-HR STATE STREET CORP 104,930 108,741 3.63 3,190 4,060 27.27
2017-02-10 13F-HR BlackRock Investment Management, LLC 1,038 1,038 0.00 16 21 31.25
2018-08-14 13F-HR TWO SIGMA ADVISERS, LP 0 6,100 0 228
2018-08-09 13F-HR BlackRock Inc. 370,386 401,019 8.27 11,259 14,974 33.00

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 887098101